This strategy would mirror the strategies in routine cardiology practice to screen patients on these conditions before cardiac drugs that block Nav1.5 channels (e.g., flecainide or other class I antiarrhythmic drugs) are considered [39], and to withhold these drugs from patients with Brugada syndrome or those who carry SCN5A mutations [44]. The gene discussed is SCN5A; the disease is Brugada syndrome.